Peninsula Research Associates, Inc. 550 Deep Valley Dr., Suite 317 Rolling Hills Est. Ca 90274 Phone 310-265-1623/Fax 310-265-1753 E-Mail: lsher@pratrials.com Laurence K. Gorlick, M.D. Office Address 550 Deep Valley Dr. Suite 319 Rolling Hills Est. Ca 90274 Phone 310-544-6858 Fax 310-544-6855
Los Alamitos, Ca 90720 Phone 562-594-9546 Clinical Research Affiliations Peninsula Research Associates, Inc. (Aug 1999- Present) 550 Deep Valley Dr. Suite 317 Rolling Hills Est. Ca 90274 Phone 310-265-1623 Fax 310-265-1753 Medical Licence California #A036580 DEA #BG3028633 Medical Education and Training College: Kingsborough Community College, Brooklyn, New York Graduated 1971, Associates in Arts Brooklyn College, Brooklyn, New York Graduated 1973, Bachelor of Arts in Psychology Curriculum Vitae Last Updated 12/02/2010
Laurence K. Gorlick, M.D. Curriculum Vitae Page 2
University Autonoma de Guadalagara ECFMG# 266-930-7
Brookdale Medical Center Brooklyn, New York Completed in 1978 Internship: Long Island College Hospital Brooklyn, New York Completed 1979 Residency: Norwalk Hospital, Internal Medicine Norwalk, Connecticut Completed 1981 Hospital Affiliations
Torrance Memorial Medical Center 3330 Lomita Blvd. Torrance, Ca 90505 310-325-9110 Little Company of Mary Hospital 4101 Torrance Blvd. Torrance, Ca 90503 Phone 310-540-7676
Curriculum Vitae Last Updated 12/02/2010
Laurence K. Gorlick, M.D. Curriculum Vitae Page 3 Awards: AMA Physician Recognition Award- January 1995 - January 2001 January 1992 - January 1995 March 1989 - January 1992 August 1986 - August 1989 August 1983 - August 1986 August 1980 - August 1983 Medical Organizations: American Society of Internal Medicine American Medical Association Los Angeles County Medical Association Long Beach Society of Internal Medicine Elected or Appointed Positions: Medical Director, ProHealth Diagnostic Services 1995-2000 Chairman- ProHealth Anciliary Services 1995-present Chairman- Credentials Committee- St. Mary Medical Center 1993-1995 Faculty Appointments: Associate Professor of Medicine UCLA St. Mary Medical Center, Long Beach, CA 1985-2006 Clinical Instructor UCLA Curriculum Vitae Last Updated 12/02/2010
Laurence K. Gorlick, M.D. Curriculum Vitae Page 4 Clinical Trial Experience:
An Open-Label, Multicenter, No-Comparative Study of Oral
Gatifloxacin in the Treatment of Community-Acquired Respiratory Tract Infections
The Micardis Community Acess Trial (MICCAT) for treatment of
Protocol AI-464-022 BMS- phase III, Acute Bacterial
Protocol AI-464-024 BMS- phase III, Acute Maxillary Sinusitis
Protocol AI-646-029 BMS- phase III, Community Acquired
Protocol CV-137-120 BMS- phase III, Comparative Trial of Two
Antihypertensive Medications in Patients With Hypertension
Eli Lilly Protocol B4Z-US-LYBV- Phase III, Randomized,
Double-Blind, Placebo-Controlled Study of Strattera in Adults with Attention-Deficit/Hyperactivity Disorder
Eli Lilly Protocol B4Z-US-LYCW: A Randomized, Double-Blind
Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adult with Attention-Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning
Merck Protocol 010-02- Phase III, Multicenter, Double-Blind,
Randomized, Placebo- and Active-Control Dose-Range Finding Study of L-000224715 in Patients with Type II Diabetes Mellitus who have Inadequate Glycemic Control
Merck Protocol 034-00- Phase III, a Multicenter, Double-Blind,
Randomized, Active Controlled, Parallel Group Study to Evaluate the Lipid-Altering Efficacy of MK0767 in Patients with Type II Diabetes and Dyslipidemia
Curriculum Vitae Last Updated 12/02/2010
Laurence K. Gorlick, M.D. Curriculum Vitae Page 5
BMS Protocol CV168-021- Phase III, randomized, double-blind,
placebo controlled, multicenter trial to evaluate safety and efficacy of BMS 298585 in combination with Glyburide in subjects with Type II Diabetes who have inadequate glycemic control on Sulfonylurea therapy alone
BMS Protocol CV168-022- Phase III, randomized, double-blind,
placebo controlled, multicenter trial to evaluate safety and efficacy of BMS 298585 study drug in combination with Metformin in subjects with Type II Diabetes who have inadequate glycemic control on Metformin alone
BMS Protocol CV168-025- Phase III, Randomized, Double-Blind,
Placebo Controlled, Multicenter Trial to Evaluate Safety and Efficacy of BMS 298585 Study Drug in Combination with Metformin in subjects with Type II Diabetes who have inadequate Metformin Control on Metformin alone
BMS Protocol CV168-006- Phase II, Randomized, Double-Blind,
Placebo Controlled, Multicenter Trial to Evaluate Safety and Efficacy of BMS 298585 Study Drug Compared to Piaglitazone in Type II Diabetics not Currently on Medication Treatment
Pfizer Protocol A3841001- Phase III, Randomized, Double-Blind,
Placebo-Controlled and Open-Label Evaluation of the Safety and Efficacy of dual Therapy with Atorvastatin Plus Amlodipine When Compared to Either Therapy Alone in the Treatment of Patients with simultaneous Hyperlipidemia and Hypertension
BMS Protocol CV137-120 -Phase III, Randomized, Placebo
Controlled Trial of Omapatralide and Enalapril
Bristol Myers Squibb, Protocol CV131-176: The Efficacy and
Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension
Bristol Myers Squibb, Protocol CV131-185: The Efficacy and
Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Moderate Hypertension
Curriculum Vitae Last Updated 12/02/2010
Medical report Name: Eman Ibrahim Wassef date of admission: 1/1/2011 Age : 48 years discharge: still in ICU treating doctors: prof. Hatem Amin Attala Concultant of anaethesiology prof. Magdy akel prof. Amin malty Consultant of ophthalmology prof. Hossam Elkafrawy Consultant of plastic surgery dr. Ehab naeem Consultant of ENT The patient was admitted to our hospital after the explosion acc
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICALREQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMANUSE ICH HARMONISED TRIPARTITE GUIDELINE DOSE-RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION This Guideline has been developed by the appropriate ICH Expert Working Groupand has been subject to consultation by the regulatory parties, in accordance with theICH Process. At Step